Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis
14th June 2016
Dermatology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given